drugset

drugset / Trial / NCT03874325

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

NCT03874325 ↗

Phase 2 Terminated 17 enrolled H. Lee Moffitt Cancer Center and Research Institute AstraZeneca · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

This study is to find out if an investigational drug called Durvalumab (MEDI4736) given together with a standard of care aromatase inhibitor drug can help people with breast cancer.

Timeline

Start: 2019-04-26
Primary completion: 2020-11-15
Completion: 2021-01-06

Publications

Soyano Muller AE, Goodridge DN, Mo Q, Whiting J, Khakpour N, Lee MC, Laronga C, Armaghani AJ, Han H, Soliman H, Costa R, Loftus L, Hoover SJ, Kiluk JV, Jameel Z, Czerniecki BJ, Khong HT. Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2026 Feb 16;216(1):11. doi: 10.1007/s10549-026-07912-w.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Durvalumab	Monoclonal antibody	1500 mg	Intravenous
Background	Anastrozole	Other / unclassified	1 mg	Oral
Background	Exemestane	Small molecule	25 mg	Oral
Background	Letrozole	Other / unclassified	2.5 mg	Oral

Indications